We looked into whether these for-profit clinics will really help you.
Category: biotech/medical – Page 2264
The Genetic Revolution
Posted in bioengineering, biotech/medical, genetics
Merry Christmas
Is the Fountain of Youth still just a dream, or does hope spring eternal when it comes to beating the curse of aging? Having haunted us for centuries, is a solution finally within our grasp? We spoke to Dr Aubrey de Grey, anti-aging pioneer, chief science officer, and co-founder of SENS Research Foundation.
Follow @SophieCo_RT
Sophie Shevardnadze: Dr. Aubrey de Grey, anti-aging pioneer, chief science officer and co-founder of SENS Research Foundation, welcome to the show, great to have you with us. So what you propose in order to reverse aging is cleaning the organism of all the junk that accumulates there on the cellular level. Tell me the gist of it – why will that stop the wearing of time on my organs?
Companies use different algorithms based on different sets of data. Most of that data comes from people of recent European ancestry.
The problem, obviously, is that a lot of people don’t have grandparents or great-great-great-grandparents from England or Italy or Denmark. Most people on Earth, actually! That means if you’re from, say, Asia or Africa, you might not get as detailed a profile as you’d like.
My mother, who was born in the Philippines, actually got an update from 23andMe with new information about her heritage. Her history didn’t change. But as the company gets more DNA kits from people of Asian descent, the algorithm churns out modified results. Which is great … but that does mean right now, if you’re not white, you might have to wait a bit longer for more accurate results.
New program coming on-line at Bioquark Inc. (www.bioquark.com) — Ectocrine interactions (the“Ectocrinome”) represents a completely unexplored area related to human health
https://www.prweb.com/releases/bioquark_inc_and_ectocrine_te…004155.htm
Building on several years of research into a protein responsible for leukemia, a newly published paper has revealed success in slowing the progression of the deadly cancer in mouse models. The researchers suggest two new prospective therapies can now be combined into one “super drug” and progress into human clinical trials.